Apogee Therapeutics Inc.
AbbVie to Acquire Apogee Therapeutics in $10.9 Billion Deal
Summary
AbbVie Inc. has entered into a definitive agreement to acquire Apogee Therapeutics, Inc. for $135.11 per share in cash, valuing the company at approximately $10.9 billion. The acquisition, which is expected to close in the third quarter of 2026, will add Apogee's diverse pipeline of clinical-stage candidates in inflammatory and immunological diseases to AbbVie's existing immunology portfolio. The transaction is expected to be accretive to AbbVie's adjusted diluted earnings per share beginning in 2032. Apogee shareholders will receive $135.11 per share in cash, and the boards of directors of both companies have unanimously approved the transaction.
Profitelligence Alerts
Get alerts for APGE
Be first to know when Apogee Therapeutics Inc. files with the SEC.
Filing Categories
Advertisement
About Apogee Therapeutics Inc.
Apogee Therapeutics Inc. is a biotechnology company focused on the development of biologic therapies for atopic dermatitis and other inflammatory diseases. The primary purpose of Apogee Therapeutics is to leverage its expertise in immunology and protein engineering to address unmet needs in the treatment of autoimmune and inflammatory conditions. The company is active in sectors such as healthcare and pharmaceuticals, contributing to advancements in medical biotechnology. Apogee Therapeutics plays a significant role in the financial market by advancing cutting-edge therapies in the biopharmaceutical landscape. It engages in research and development efforts to bring innovative biologic medicines to patients, thereby impacting the broader pharmaceutical industry. The company's focus on treating inflammatory diseases aligns with an increasing demand for novel treatments arising from a greater understanding of disease mechanisms and patient needs. By developing specialized biologic solutions, Apogee Therapeutics positions itself as a key player in addressing some of the challenges associated with chronic inflammatory conditions, ultimately pushing forward the boundaries of therapeutic options available to patients worldwide.
Official SEC Documents
Advertisement